Will Baxter record a goodwill impairment charge in FY2026?

The market cap ($8.8B) is below the Hillrom acquisition price ($12.5B), creating a massive gap between carrying value and market value. Under ASC 350, companies must test goodwill annually and whenever triggering events occur. The operating model restructuring (removing Hillrom-era segment structure) likely qualifies as a triggering event requiring interim testing. BAX's new reporting unit structure may force allocation testing that reveals impairment at the individual unit level. However, management can use qualitative assessments and DCF models (which may show higher values than market cap), providing some discretion.

Goodwill impairment is a function of both the gap between carrying value and fair value AND management's willingness to take the charge. Management has discretion in DCF assumptions — using optimistic long-term growth rates and discount rates, they can potentially justify carrying values above market cap. Companies frequently delay impairment charges during turnarounds, arguing that the stock price reflects temporary pessimism rather than fundamental value. Given that management is trying to execute a recovery, they may resist formalizing the value destruction. Perhaps 55% probability.

The reporting unit restructuring under the new operating model is a critical factor. When companies restructure reporting units, they must reallocate goodwill and test at the new unit level. This reallocation process often surfaces impairment that was previously masked at higher aggregation levels. Given the scale of the gap ($8.8B market cap vs. likely $10B+ in goodwill on the balance sheet), auditors will push hard for a quantitative test. The combination of restructured reporting units, persistent stock price depression, and auditor scrutiny creates a roughly 58% probability of impairment in 2026.

The gap between market cap and book value is too large to ignore. BAX's market cap of $8.8B vs. $12.5B Hillrom acquisition price (plus existing goodwill) means total goodwill likely exceeds $10B against a sub-$9B market cap. Auditors will require at least a quantitative step-one test, and it will be very difficult for management's DCF to justify carrying values 40%+ above market cap. The operating model restructuring adds a triggering event. I estimate 65% probability of some goodwill charge in FY2026.

While the conditions strongly favor impairment (market cap below acquisition price, declining earnings, restructured operations), there are paths to NO: management uses aggressive DCF assumptions, auditors accept a qualitative assessment for 2026 annual test, or the stock recovers meaningfully. The turnaround narrative gives management some cover for optimistic long-term assumptions. A significant stock recovery before year-end (unlikely given analysis) would also avoid impairment. I estimate 58%.

The new CEO may actually prefer to take the impairment — it formalizes the predecessor's bad acquisition, resets expectations, and creates a cleaner baseline for measuring the turnaround. This is a common turnaround playbook: new management takes a 'kitchen sink' quarter to write down legacy issues. Combined with the triggering event from restructuring and auditor pressure, I estimate 60% probability.

Market cap well below Hillrom acquisition price. Operating model restructuring triggers testing. Auditors will push hard. About 60% chance of goodwill charge in FY2026.

The impairment conditions are present but management has discretion via DCF assumptions. May defer to allow turnaround to demonstrate progress first. Slightly above coin-flip probability.

New management often takes write-downs early to reset baselines. The gap between market and book value is substantial. Restructuring changes reporting units. About 58% probability of a goodwill charge.